Pfizer has initiated a legal battle against Metsera and Novo Nordisk, accusing Metsera of violating a merger agreement due to Novo Nordisk's $8.5 billion bid being declared superior. Pfizer is calling on a Delaware court to prevent Metsera from ending their deal, seeking a temporary restraining order ahead of an upcoming shareholder vote.

In a parallel development, the U.S. Federal Trade Commission granted Pfizer early antitrust clearance for its planned $7.3 billion acquisition of Metsera. Despite this, Novo Nordisk, already a major player in the obesity drug market, is aggressively pursuing Metsera to regain lost market share, leading to claims by Pfizer of a competitive suppression attempt.

Negotiations have been intense, with both Pfizer and Novo Nordisk making multiple bids througho

See Full Page